Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · STAAR Surgical (STAA)

STAAR Surgical Q4 sales up 18.1%; full-year net loss widens to $80.4 million

Mixed Impact 3 of 5 earnings Written later

STAAR Surgical reported fourth-quarter 2025 net sales of $57.8 million, up 18.1%, and a narrower net loss of $18.3 million versus $34.2 million a year earlier. For the full year, net sales fell 23.7% to $239.4 million and the net loss widened to $80.4 million, or $1.62 per share, from $20.2 million, or $0.41 per share. Shareholders face a mixed picture: quarterly results improved, but the annual decline and larger loss reflect the China inventory reduction and merger-related costs.

Key points

  • Q4 2025 net sales $57.8 million, up 18.1%; net sales excluding China $40.3 million, down 2.1%
  • Q4 2025 net loss $(18.3) million, or $(0.37) per share, versus $(34.2) million, or $(0.69) per share, a year earlier
  • Full-year 2025 net loss $(80.4) million, or $(1.62) per share; Q4 included $11.2 million in costs tied to the terminated Alcon merger
  • Cash, cash equivalents and investments available for sale were $187.5 million at January 2, 2026, with no outstanding debt

The filing

CompanySTAAR Surgical (STAA)
Form8-K, current report
Filed with the SECMar 3, 2026, 4:05 PM ET
Accession number0000718937-26-000005

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.